I think the market response to this announcement has been quite...

I think the market response to this announcement has been quite underwhelming. What the market doesn't seem to realise yet, is that this announcement alludes to be quite an important announcement relating to a commercially unaccounted for vertical. None of the JVs play in this space and it seemed biotech was a ways off.

There are cancer treatments where BNNT is used for the process of boron neutron capture treatment or BNCT.

Filgen is a Japanese biotech supply company. After doing a little reading into BNCT, there is an article from Physics World, October 2020, stating that Japan has performed a vast majority of these BNCT procedures globally and now has, thanks to Sumitomo, the first approved BNCT accelerator (Japan has three as of that date).

I cannot state if BNNTs are used in these procedures as other boron products can be used, but an important door has been opened, commercially introducing Deakins BNNTs to the biotech industry where PPK had otherwise not been playing.

Does anyone have better insight into this?

This is an attempt to connect dots, not give advice.